Cure8 research brief
Perianal fistulizing Crohn's disease is a disabling complication; a subcutaneous form of infliximab could lower treatment burden and expand options if its effectiveness and safety in this specific setting are confirmed.
Adults with Crohn's disease and perianal fistulas, gastroenterologists and colorectal surgeons involved in pfCD care, and researchers studying biologic delivery methods.
The longstanding standard for treating pfCD is IV infliximab, supported by guidelines and trial data. SC infliximab is a newer delivery option that offers self-administration and may reduce treatment burden. Available evidence in pfCD comes mainly from prospective and retrospective real-world studies rather than pfCD-specific randomized controlled trials.
These studies report sustained clinical and radiological remission and low recurrence rates, but sample sizes and follow-up vary and prospective pfCD-focused trials are limited.
If you are considering SC infliximab, discuss with your care team whether existing data apply to your situation, and whether monitoring of drug levels or imaging will be needed to assess fistula healing.
This article is a review/abstract summarizing available real-world studies and highlights gaps: randomized controlled trials and pfCD-specific radiologic outcome studies are limited. The source is an academic journal review (abstract-level content).
Review the original publication for the complete reporting, methods, and context.
Conflict statement: A.D. reports fees for participation in clinical trials, review activities such as data monitoring boards, statistical analysis, and end point committees from Abivax, AbbVie, Falk, Galapagos, Gilead, J&J, Pfizer, and Takeda; consultancy fees from AbbVie, Alfasigma, Amgen, Biogen, Boehringer Hexal, J&J, Lilly, MSD, Pfizer, Pharmacosmos, Roche, Sandoz, Stada, Takeda, and Vifor Pharma; payment from lectures including service on speakers bureaus from AbbVie, Alfasigma, Biogen, CED Service GmbH, Celltrion, Falk, Fresenius Kabi, Ferring, Galapagos, Gilead, Hexal, High5MD, J&J, Materia Prima, MedToday, MSD, Pfizer, Sandoz, Streamed-Up, Takeda, and Vifor Pharma; payment for manuscript preparation from Abbvie, Falk, J&J, Takeda, Thieme, and UniMed Verlag. C.R. reports fees for participation in clinical trials, review activities such as data monitoring boards, consultancy fees, travel fees, speaking fees from AbbVie, Falk, Galapagos, J&J, Pfizer, Roche, Sandoz, Lilly, Alfasigma, Biogen, Thermofisher, Fresenius Kabi, Ferring. A.B.: reports consulting fees from: AbbVie, Amgen, Arena, Biogen, Celltrion Healthcare, CTMA, Ferring, Galapagos/AlfaSigma, GutyCare/Resilience, Hikma, Janssen, Lilly, MSD, Nexbiome, Pfizer, Roche, Sandoz, Takeda, Tillotts. Lecture fees from: AbbVie, Amgen, Biogen, Celltrion Healthcare, Galapagos/AlfaSigma, Ferring, Hikma, Janssen, Lilly, Mayoli-Spindler, MSD, Nordic Pharma, Norgine, Pfizer, Roche, Takeda, Tillotts, Vifor Pharma. Research funding from: AbbVie, Celltrion Healthcare, Janssen, Galapagos/AlfaSigma, Lesaffre, Lilly, Pfizer, Sandoz, Takeda. F.M. has served as a speaker and received honoraria from Merck Sharp & Dohme, AbbVie, Vifor, Falk, Laboratorios Vitoria, Ferring, Hospira, and Biogen. L.V. has received speaker and/or consulting fees from AbbVie, Amgen, Takeda, Celltrion, Pfizer, Johnson & Johnson, MSD, Ferring, Lilly, Viatris, Galapagos, Alpha-sigma, Dr Falk Pharma, Nordic Pharma, Biocon. S.P., M.J.P. are employees of Celltrion, Inc. B.E.S.: reports consulting fees from AbbVie, Alimentiv, Adiso Therapeutics, Agomab, Amgen, AnaptysBio, Astra Zeneca, Biolojic Design, Biora Therapeutics, Boehringer Ingelheim, Equillium, Ensho Therapeutics, Enthera, Enveda Biosciences, Evommune, Ferring, Fzata, Galapagos, Genentech (Roche), Gilead Sciences, GlaxoSmithKline, Gossamer Bio, Imhotex, Immunyx Therapeutics, Index Pharmaceuticals, Innovation Pharmaceuticals, Kaleido, Kallyope, Merck & Co., Microba, Microbiotica, Mitsubishi Tanabe Pharma, Mobius Care, Morphic Therapeutics, MRM Health, Nexus Therapeutics, Nimbus Discovery, Odyssey Therapeutics, Palisade Bio, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Q32 Bio, Rasayana Therapeutics, Recludix Therapeutics, Reistone Biotherapeutics, Sanofi, Sorriso Pharmaceuticals, Surrozen, Target RWE, Teva, TLL Pharmaceutical, TR1X, Union Therapeutics; consulting and speaking fees from Abivax; consulting and speaking fees and other support from Celltrion and Lilly; research grants, consulting and speaking fees, and other support from Bristol Myers Squibb, Janssen/J&J Innovative Medicine, Pfizer, Takeda; research grants and consulting fees from Theravance Biopharma; and consulting fees, stock, and stock options from Ventyx Biopharma.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study suggests starting anti-TNF drugs early in children with Crohn's could strongly lower the chance of developing anal fistulas, a serious complication that often requires surgery. Preventing fistulas can reduce...
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
Subcutaneous infliximab may let children on infliximab avoid regular IV infusions while keeping drug levels high and maintaining remission. Results are relevant to families and clinicians considering switching pediatric...
